Calidi Biotherapeutics Launches CLD-101 Trial for Brain Cancer

Calidi Biotherapeutics has announced that Northwestern University is now recruiting patients for the CLD-101 clinical trial, a cutting-edge immunotherapy designed for high-grade glioma, an aggressive brain cancer. CLD-101 consists of allogeneic neural stem cells carrying an oncolytic adenovirus, CRAd-S-pk7, and has shown promising early results in a previous Phase 1 trial. The new Phase 1B/2 study, led by Dr. Maciej Lesniak and Dr. Roger Stupp, will evaluate multiple doses in newly diagnosed patients to enhance therapeutic efficacy. Funded by the NIH/NCI SPORE, the study marks a crucial step in advancing virotherapy for brain tumors.

Dr. Lesniak expressed optimism about the improved treatment regimen, emphasizing the importance of early intervention. Dr. Stupp, renowned for his groundbreaking contributions to glioblastoma therapy, joins a world-class team in leading the trial. Calidi Biotherapeutics CEO Allan Camaisa highlighted the potential impact of CLD-101, stating that if results mirror prior findings, the implications could be transformative for brain cancer treatment. With this trial and its systemic virotherapy platform, Calidi aims to revolutionize treatments for glioblastoma and other solid tumors.